Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report [Yahoo! Finance]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: Yahoo! Finance
The results overall were pretty good, with revenues of US$7.8m exceeding expectations and statutory losses coming in at justUS$0.31 per share, some 30% below what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. See our latest analysis for Foghorn Therapeutics Following the latest results, Foghorn Therapeutics' eight analysts are now forecasting revenues of US$34.1m in 2025. This would be a substantial 34% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 14% from last year to US$1.41. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$34.9m and losses of US$1.51 per share in 2025. It looks like there's
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore BiotechnologiesPR Newswire
- Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with PfizerPR Newswire
- Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-PartnerPR Newswire
- Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori BioPR Newswire
- Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 11/4/24 - Beat
FHTX
Sec Filings
- 11/4/24 - Form 10-Q
- 11/4/24 - Form 8-K
- 10/10/24 - Form 8-K
- FHTX's page on the SEC website